Resistance to anti-estrogen therapy in breast cancer due to natural cell response

April 4, 2011

Most breast cancers are fueled by estrogen, and anti-estrogenic agents often work for a time to control the cancers. But many of these cancers become resistant to the drugs for reasons that are not understood, leaving patients with limited treatment options.

Now researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center (GUMC), say that this resistance appears to be due to a natural in cells, and that the biochemical molecules involved in this response might prove to be a new drug target. They reported their findings at the American Association for Cancer Research (AACR) 102nd Annual Meeting 2011.

They found that cells protect themselves against two anti-estrogen drugs (Tamoxifen and Faslodex) by hijacking and switching on a biological process inside the cells that is normally used when proteins are produced that don't have the right shape.

It had not been known, before this study, that this program - the "unfolded protein response" or UPR - could be triggered when breast cancer cells are "attacked" by anti-estrogen drugs, says the study's lead investigator, Ayesha Shajahan, Ph.D., an oncology researcher instructor and researcher in the laboratory of Robert Clarke, Ph.D., D.Sc., Dean for Research at GUMC. Clarke will be presenting the results at AACR.

If a UPR is activated, a cell can do one of two things, Shajahan says: it can turn on a pro-survival pathway or it can turn on a process that ultimately destroys the cell. The cells they studied all chose to "man the forts" to survive. They hunker down and wait out the attack, a tactic that allows the cell to resist anti-cancer treatment.

"We found that anti-estrogen resistant cancer cells are much more likely to turn on the pro-survival pathway than are cells that are sensitive to estrogen," says Shajahan.

They also found that anti-estrogen resistant over-express the X-Box (XBP1), which turns on UPR signaling, and that specific resistance to Faslodex (Fulvestrant) occurs because of increased levels of over-expression of a XBP1 subtype, XBP1(s).

Related Stories

Recommended for you

Cancer-death button gets jammed by gut bacterium

July 27, 2017
Researchers at Michigan Medicine and in China showed that a type of bacterium is associated with the recurrence of colorectal cancer and poor outcomes. They found that Fusobacterium nucleatum in the gut can stop chemotherapy ...

Researchers release first draft of a genome-wide cancer 'dependency map'

July 27, 2017
In one of the largest efforts to build a comprehensive catalog of genetic vulnerabilities in cancer, researchers from the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have identified more than 760 genes ...

Long-sought mechanism of metastasis is discovered in pancreatic cancer

July 27, 2017
Cells, just like people, have memories. They retain molecular markers that at the beginning of their existence helped guide their development. Cells that become cancerous may be making use of these early memories to power ...

Blocking the back-door that cancer cells use to escape death by radiotherapy

July 27, 2017
A natural healing mechanism of the body may be reducing the efficiency of radiotherapy in breast cancer patients, according to a new study.

Manmade peptides reduce breast cancer's spread

July 27, 2017
Manmade peptides that directly disrupt the inner workings of a gene known to support cancer's spread significantly reduce metastasis in a mouse model of breast cancer, scientists say.

Glowing tumor technology helps surgeons remove hidden cancer cells

July 27, 2017
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) - through the use of a contrast agent that makes tumor cells ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.